A Look At BrightSpring Health Services (BTSG) Valuation After Earnings Beat And Higher 2026 Guidance

BrightSpring Health Services (BTSG) heads into its May 12 presentation at the Bank of America Global Healthcare Conference shortly after reporting an earnings beat and raising full-year 2026 revenue guidance, which has drawn fresh attention to the stock.

See our latest analysis for BrightSpring Health Services.

The stock has rallied strongly in recent months, with a 30-day share price return of 22.49% and year-to-date share price return of 50.78%, while the 1-year total shareholder return of 140.15% points to powerful momentum around the earnings beat and higher guidance.

If this kind of healthcare move has your attention, it can be a good time to see what else is gaining traction through our screener of 29 healthcare AI stocks.

With BrightSpring now trading close to analysts’ average price target after a strong run and a price that implies a steep discount to some intrinsic value estimates, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 3% Undervalued

BrightSpring's most followed narrative puts fair value at $59.60, slightly above the last close of $57.90, which suggests only a modest valuation gap.

The analysts have a consensus price target of $59.6 for BrightSpring Health Services based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $65.0, and the most bearish reporting a price target of just $48.0.

Read the complete narrative.

Curious what is baked into that fair value? The narrative leans heavily on sustained revenue expansion, rising margins, and a richer earnings profile several years out.

Result: Fair Value of $59.60 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that narrative can quickly be tested if labor costs stay elevated or if the integration of recent acquisitions drags on margins and earnings expectations.

Find out about the key risks to this BrightSpring Health Services narrative.

Another View: Rich Multiples Raise the Bar

That 3% undervaluation narrative sits awkwardly beside what the current multiples are saying. BrightSpring trades on a P/E of 69.6x, which is much higher than the US Healthcare industry at 22.4x, the peer average at 20.3x, and even its own fair ratio of 35.2x.

In practical terms, the stock already prices in a lot of future earnings power, so any stumble on margins, integration, or growth could hit sentiment quickly. The question for you is whether the cash flow outlook is strong enough to justify this kind of premium.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Seen enough to form an early view, or still on the fence about where sentiment goes from here? Move quickly, review the key data points yourself, and consider both the upside potential and the areas of concern with our breakdown of 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If BrightSpring has sharpened your interest, do not stop here. Broaden your watchlist with a few focused stock ideas that could sharpen your overall portfolio thinking.

• Spot potential value opportunities early by scanning our set of screener containing 21 high quality undiscovered gems that pair strong fundamentals with relatively low investor attention.
• Strengthen your portfolio's foundation with companies highlighted in the solid balance sheet and fundamentals stocks screener (45 results) that emphasize financial resilience and disciplined capital structures.
• Dial back portfolio risk without going to cash by reviewing 66 resilient stocks with low risk scores that emphasize steadier business profiles and lower risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com